IMMUNOMEDICS, INC.;CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY
发明人:
GOLDENBERG, DAVID M.,CHANG, CHIEN HSING,TAYLOR, ALICE P.
申请号：
CA2625992
公开号：
CA2625992C
申请日:
2006.10.16
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
The present invention concerns methods and compositions for inhibitingangiogenesis and/or tumor growth, survival and/or metastasis. In particularembodiments, the methods and compositions may concern ligands against placentagrowth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods maycomprise administering one or more PlGF ligands, alone or in combination withone or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agentsto a subject. The PlGF ligands are effective to inhibit angiogenesis, tumorcell motility, tumor metastasis, tumor growth and/or tumor survival. Incertain embodiments, PlGF ligands may be administered to subjects toameliorate other angiogenesis related conditions, such as maculardegeneration. In some embodiments, PlGF expression levels may be determined byany known method to select those patients most likely to respond to PlGFtargeted therapies.
